Ally Bridge MedAlpha Master Fund L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 4:17 pm Purchase |
2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Ally Bridge MedAlpha Master Fund L.P. | 393,052 6.300% |
89,740 (+29.59%) |
Filing |
| 2020-12-18 4:20 pm Purchase |
2020-12-08 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Ally Bridge MedAlpha Master Fund L.P. | 303,313 5.400% |
303,313 (New Position) |
Filing |